Evaluation of Guselkumab Efficacy and Safety in Fistulizing Perianal Crohn's Disease: A Phase 3 Randomized, Placebo-Controlled, Multicenter Study

The primary objective of this Phase 3, randomized, placebo-controlled, parallel-group, multicenter study is to evaluate the clinical efficacy of **guselkumab** in patients with fistulizing, perianal Crohn's disease. This objective is clinically relevant as it aims to determine the therapeutic potential of guselkumab, a monoclonal antibody, in managing a challenging manifestation of Crohn's disease, which significantly impacts patient quality of life and is often resistant to conventional treatments.

The clinical trial investigating the efficacy of guselkumab in **fistulizing perianal Crohn's Disease** includes a total of 90 participants. The study population comprises both male and female subjects aged 18 years and older. Participants were selected based on specific criteria, including a confirmed diagnosis of Crohn's disease with a minimum duration of three months and the presence of at least one active draining perianal fistula, as verified by screening MRI results. The trial includes individuals who have previously shown a lack of response or intolerance to a maximum of two classes of biologic agents or have a history of failure to respond to or tolerate certain therapies for Crohn's disease and fistula treatment. The trial population is characterized by a diverse age range and includes vulnerable populations, ensuring a comprehensive evaluation of the treatment's efficacy across different demographics. Lifestyle factors such as diet and physical activity were not specified in the available data.

The clinical trial is a **Phase 3**, randomized, placebo-controlled, parallel-group, multicenter study designed to evaluate the efficacy and safety of **guselkumab** in participants with fistulizing, perianal **Crohn's disease**. The trial aims to assess the clinical efficacy of guselkumab, a monoclonal antibody, in achieving combined fistula remission by Week 24. The study is expected to run until May 2027, with recruitment having commenced in February 2023.

Participants will be randomly assigned to receive either guselkumab or a placebo. The trial employs a double-blind methodology to ensure unbiased results. The study will involve multiple visits, starting with an inclusion (screening) visit to confirm eligibility based on criteria such as age (18 years or older), a diagnosis of Crohn's disease for at least three months, and the presence of at least one active draining perianal fistula confirmed by MRI. Participants must also have a history of inadequate response or intolerance to certain therapies for Crohn's disease and fistula treatment.

Following the screening, participants will attend regular follow-up visits to monitor their response to the treatment and any adverse effects. These visits will include assessments of the primary endpoint, which is the proportion of participants achieving combined fistula remission at Week 24. The end-of-study visit will conclude the participant's involvement, which is expected to last up to 85 weeks, depending on the treatment arm and individual response.

Participants may be withdrawn from the study early if they experience significant adverse effects, fail to adhere to the study protocol, or if the investigator deems it necessary for their safety. The trial is conducted under strict ethical guidelines to ensure the safety and well-being of all participants.

The clinical trial involves the administration of **Guselkumab**, a monoclonal antibody, in two pharmaceutical forms. The first form is a **solution for infusion** with a concentration of 10 mg/mL. This formulation is administered intravenously, with the maximum treatment period set at 8 weeks. The infusion is prepared and delivered under controlled conditions to ensure precise dosing and participant safety. Compliance with the infusion schedule is monitored through regular assessments and documentation by clinical staff.

The second form of **Guselkumab** is a **solution for injection in a pre-filled syringe** with a concentration of 100 mg/mL. This formulation is intended for subcutaneous use, with a maximum treatment period of 85 weeks. The injection is facilitated by the YpsoMate device, a 2-step autoinjector that ensures automatic dose delivery after manual activation. The device includes a permanently bonded needle to enhance safety and ease of use. Participant adherence to the injection schedule is tracked through electronic diaries and periodic clinic visits.

In addition to the experimental treatments, the study includes a **placebo** group. The placebo is designed to match the **Guselkumab** formulations in appearance and administration route, ensuring blinding of participants and investigators. The placebo for the solution for infusion and the solution for injection in a pre-filled syringe is administered following the same schedule and conditions as the active treatment groups. Monitoring of participant compliance and adverse events is conducted consistently across all groups to maintain the integrity of the trial data.

The efficacy of **guselkumab** in the treatment of fistulizing, perianal Crohn's disease will be assessed in a Phase 3, randomized, placebo-controlled, parallel-group, multicenter study. The primary endpoint for evaluating efficacy is the proportion of participants who achieve combined fistula remission at Week 24. This endpoint will be measured and analyzed to determine the effectiveness of the treatment in achieving the desired clinical outcome. The study will involve the administration of guselkumab as a solution for infusion or injection, with the treatment period extending up to 85 weeks. The trial aims to provide comprehensive data on the clinical efficacy of guselkumab in this specific patient population.